RxDoctor Payments DataLook up a doctor →

Shannon Woods

Gerontology · Southaven, MSNPI 1487072864

Payments from drug & device makers

$14,283in general payments, 2019–2025

Across 549 payments — averaging $26.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$3K
  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • Mylan Specialty L.p.$643
  • Actelion Pharmaceuticals US, Inc.$601
  • plus $5K from 31 others

What the payments were for

  • Consulting fees$2,34016%
  • Food & beverage$11,73782%
  • Education$2061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,283 in reported general payments places this provider in the 95th percentile of 66 gerontology providers in Mississippi.

See all gerontology providers in Mississippi

Medicare billing

Part B allowed, 2024
$40,343
Medicare patients
354
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter287$243,742
XolairOmalizumab22$88,436
Breo ElliptaFluticasone/Vilanterol109$69,535
Breztri AerosphereBudesonide/Glycopyr/Formoterol96$68,089
NucalaMepolizumab14$60,703
Dupixent PenDupilumab13$49,326
Spiriva RespimatTiotropium Bromide47$30,813
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$30,595
Stiolto RespimatTiotropium Br/Olodaterol Hcl43$27,442
SymbicortBudesonide/Formoterol Fumarate55$15,484
Spiriva HandihalerTiotropium Bromide19$11,580
Albuterol Sulfate HfaAlbuterol Sulfate323$9,729
Advair HfaFluticasone Propion/Salmeterol21$8,901
Incruse ElliptaUmeclidinium Bromide25$7,808
Bevespi AerosphereGlycopyrrolate/Formoterol Fum16$6,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta$1,698$415,729498 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,774$90,183167 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$1,216$63,984102 claims
MerckDulera$247$6,03418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 66 gerontology providers in Mississippi.

Other gerontology in Southaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →